Colleen Lewis

2.6k total citations
27 papers, 406 citations indexed

About

Colleen Lewis is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Colleen Lewis has authored 27 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Hematology. Recurrent topics in Colleen Lewis's work include Multiple Myeloma Research and Treatments (7 papers), Ethics in Clinical Research (6 papers) and Protein Degradation and Inhibitors (5 papers). Colleen Lewis is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Ethics in Clinical Research (6 papers) and Protein Degradation and Inhibitors (5 papers). Colleen Lewis collaborates with scholars based in United States, Switzerland and India. Colleen Lewis's co-authors include R. Donald Harvey, Taofeek K. Owonikoko, Fadlo R. Khuri, Rebecca D. Pentz, Margaret White, Yuan Liu, Suresh S. Ramalingam, Sagar Lonial, Charise Gleason and Jonathan L. Kaufman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Colleen Lewis

25 papers receiving 396 citations

Peers

Countries citing papers authored by Colleen Lewis

Since Specialization

Citations

This map shows the geographic impact of Colleen Lewis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colleen Lewis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colleen Lewis more than expected).

Fields of papers citing papers by Colleen Lewis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colleen Lewis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colleen Lewis. The network helps show where Colleen Lewis may publish in the future.

Co-authorship network of co-authors of Colleen Lewis

This figure shows the co-authorship network connecting the top 25 collaborators of Colleen Lewis. A scholar is included among the top collaborators of Colleen Lewis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colleen Lewis. Colleen Lewis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Comparison of sociodemographic characteristics of a phase 1 clinical trial population at an NCI-designated comprehensive cancer center in the Southeast to catchment area.	Journal of Clinical Oncology	Jeffrey M. Switchenko, Madhusmita Behera et al.	0
2	Therapeutic Misconception about Research Procedures: Does a Simple Information Chart Improve Understanding?	PubMed	Gavin P. Campbell, Colleen Lewis et al.	2
3	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma	Clinical Lymphoma Myeloma & Leukemia	Jonathan L. Kaufman, Roberto Mina et al.	5
4	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma	British Journal of Cancer	R. Donald Harvey, Bradley Curtis Carthon et al.	11
5	Precision Oncology Comes of Age: Tumor-Agnostic Approaches	Journal of the Advanced Practitioner in Oncology	Colleen Lewis, R. Donald Harvey	1
6	Provider Recommendations for Phase I Clinical Trials Within a Shared Decision-Making Model in Phase I Cancer Clinical Trial Discussions	JCO Oncology Practice	Gavin P. Campbell, Colleen Lewis et al.	1
7	Effect of informational charts on patient understanding of nontherapeutic research procedures in phase I trials.	Journal of Clinical Oncology	Gavin P. Campbell, Colleen Lewis et al.	1
8	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy	BMC Cancer	Mehmet Asım Bilen, Julie M. Shabto et al.	86
9	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study	Blood Cancer Journal	Jonathan L. Kaufman, Roberto Mina et al.	44
10	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials	Oncology	Taofeek K. Owonikoko, Sungjin Kim et al.	3
11	Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies	Clinical journal of oncology nursing	Colleen Lewis	0
12	Abstract C26: Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents	Cancer Epidemiology Biomarkers & Prevention	Taofeek K. Owonikoko, Colleen Lewis et al.	1
13	First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors.	Journal of Clinical Oncology	John Sarantopoulos, Michael S. Gordon et al.	14
14	Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.	Journal of Clinical Oncology	Nabil F. Saba, Scott A. Kono et al.	2
15	Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials	Cancer	Rebecca D. Pentz, Margaret White et al.	112
16	A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies.	Journal of Clinical Oncology	John Kauh, R. Donald Harvey et al.	5
17	A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.	Journal of Clinical Oncology	Taofeek K. Owonikoko, R. Donald Harvey et al.	3
18	Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study	Blood	Jonathan L. Kaufman, Jatin J. Shah et al.	3
19	Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results	Journal of Clinical Oncology	Christopher R. Flowers, Jonathan L. Kaufman et al.	1
20	Abstract No. 65: Catheter Thrombolysis in Thrombocytopenic Cancer Patients with Deep Vein Thrombosis	Journal of Vascular and Interventional Radiology	Abbas Chamsuddin, Toufic Kabbani et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact